Concord Biotech Limited (BOM:543960)
India · Delayed Price · Currency is INR 1,269.05
-109.30 (-7.93%)
At close: Oct 28, 2026
Concord Biotech Revenue
In the fiscal year ending March 31, 2026, Concord Biotech had annual revenue of 10.55B INR, down -12.10%.
Revenue
10.55B
Revenue Growth
-12.10%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1,624
Market Cap
132.71B
Revenue by Geography
- India 5.64B 53.4%
- Others 3.83B 36.3%
- America 1.08B 10.2%
Fiscal year ended Mar 31, 2026 See the full Concord Biotech breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 10.55B | -1.45B | -12.10% |
| Mar 31, 2025 | 12.00B | 1.83B | 18.01% |
| Mar 31, 2024 | 10.17B | 1.64B | 19.20% |
| Mar 31, 2023 | 8.53B | 1.40B | 19.67% |
| Mar 31, 2022 | 7.13B | 959.91M | 15.56% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Biocon | 173.21B |
| Dishman Carbogen Amcis | 29.01B |
| Anthem Biosciences | 20.07B |
| OneSource Specialty Pharma | 15.43B |
| Concord Biotech | 11.08B |
| Blue Jet Healthcare | 8.86B |
| Supriya Lifescience | 8.73B |
| Panacea Biotec | 6.73B |
Concord Biotech News
- 20 hours ago - Concord Biotech Quarterly report: Q2 2027 - Filings
- 2 months ago - Concord Biotech Transcript: Q1 26/27 - Transcripts
- 2 months ago - Concord Biotech Quarterly report: Q1 2027 - Filings
- 2 months ago - Concord Biotech Slides: Q1 2027 - Filings
- 4 months ago - Concord Biotech Transcript: Q4 25/26 - Transcripts
- 4 months ago - Concord Biotech Quarterly report: Q4 2026 - Filings
- 4 months ago - Concord Biotech Slides: Q4 2026 - Filings
- 4 months ago - Concord Biotech Annual report: Q4 2026 - Filings